^Manera C, Tuccinardi T, Martinelli A. Indoles and related compounds as cannabinoid ligands. Mini Rev Med Chem. 2008, 8 (4): 370–87. PMID 18473928. doi:10.2174/138955708783955935.
^Wiley JL, Marusich JA, Thomas BF. Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids. Curr Top Behav Neurosci. Current Topics in Behavioral Neurosciences. 2017, 32: 231–248. ISBN 978-3-319-52442-9. PMID 27753007. doi:10.1007/7854_2016_17.
^Banister SD, Connor M. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. Handb Exp Pharmacol. Handbook of Experimental Pharmacology. 2018, 252: 165–190. ISBN 978-3-030-10560-0. PMID 29980914. doi:10.1007/164_2018_143.
^ 7.07.17.27.37.47.57.6Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR. 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorganic & Medicinal Chemistry. December 1999, 7 (12): 2905–14. PMID 10658595. doi:10.1016/s0968-0896(99)00219-9.
^Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett RD, Reggio PH. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. Journal of Medicinal Chemistry. September 1996, 39 (20): 3875–7. PMID 8831752. doi:10.1021/JM960394Y.
^Bow EW, Rimoldi JM. The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspect Medicin Chem. 2016 Jun 28;8:17-39. doi:10.4137/PMC.S32171PMID27398024
^Huffman JW, Bushell SM, Miller JR, Wiley JL, Martin BR. 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorganic & Medicinal Chemistry. December 2002, 10 (12): 4119–29. PMID 12413866. doi:10.1016/s0968-0896(02)00331-0.